MD, Chicago Medical School
GENA-05: "Immunogenicity, efficacy and safety of treatment with Human-cl rhFVIII in previously untreated patients with severe hemophilia A", Co Investigator
CSL 627-3001: "Extension trial: Safety and efficacy of CSL 627 in the treatment of hemophilia A", Co Investigator
GENA-21b: "Prospective, open-label, multicentre phase 3b study to assess the efficacy and safety of personalized prophylaxis with Human-cl rhFVIII in previously treated adult patients with severe haemophilia A", PI
H13-21115: "Identification and monitoring of acute joint bleeding using ultrasonography and blood biomarkers.", Co Investigator
"Hemophilia Inhibitor Research Study (HIRS) -- Phase III Inhibitor surveillance study.", Co Investigator
998HB303" Open-label, multicenter evaluation of the safety & efficacy or recombinant, long-acting coagulation factor IX Fc fusion protein (rFIXFc) in the prevention & treatment of bleeding in previously untreated patients with severe Hemophilia B, ", Co Investigator
Project # CDC-RFA-DD11-1103: "Public Health Surveillance Prevention of Complications of Bleeding and Clotting Disorders", PI
"COMMUNITY COUNTS-Registry for Bleeding Disorders Surveillance", PI
"ATHN Data Set: Portal submission for Webtracker / Clinical Manager and the ATHN dataset.", PI
ATHN2014-MLOF-2: "My Life, Our Future: GenotyPrincipal Investigatorng for patients diagnosed with hemophilia A or B.", Co Investigator
03-585: "KidsDOTT, Prospective Multi-center evaluation of the duration of therapy for thrombosis in children: ", PI
CSL 627-3002: "Hemophilia A pediatric study", Co Investigator
"R01 Comparative Effectiveness in the diagnosis of VWD", PI
"Molecular and Clinical Biology of VWD", Co Investigator
"Expression of Biomarkers in Hemophilic Arthropathy", Co Investigator
"Prospective inceptional cohort study (Principal InvestigatorCS) of individuals with bleeding and clotting disorders. ", Co Investigator
RB-FVIIa-006-13: "A randomized, Open-Label Study to Evaluate the PK and Safety of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc: BIIB031) Manufactured at 15K Scale and at Vial Strengths up to 6000IU in Previously Treated Subjects with Severe Hemophilia A", Co Investigator